Chief Scientific Officer at BTG plc*
Date of birth: July 29, 1958
First elected: May 2017
Term expires: General Meeting 2021
Business address: 54, rue la Boétie – 75008 Paris (France)
Independent director / Member of the Scientific Committee
Directorships and appointments outside the Sanofi Group
Directorships as of 12/31/2017
- Director of Think10 (United Kingdom)
Past directorships expiring within the last five years
- Director of Syntaxin Ltd.* (United Kingdom), BTG plc.* (United Kingdom), Lundbeck A/S (Denmark), NightstaRx Ltd. (United Kingdom)
(*) Listed companies are indicated by an asterisk.
Education and business experience
Melanie Lee received an undergraduate degree in Biology from the University of York and then a Ph.D. at National Institute for Medical Research in London.
She is Chief Scientific Officer at BTG plc since November 2014, a company which operates in interventional medicine in vascular disease, oncology and pulmonology.
She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund’s Lincoln’s Inn Laboratories. Following her academic career she spent 10 years at Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as Executive Director of Research. Celltech plc was subsequently acquired by UCB where she became Executive Vice President, Research & Development. After leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona backed company in 2014.
Melanie received her CBE for services to medical science in 2009.